-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Tops Q2 EPS by 37c ; Offers Guidance
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Tops Q4 EPS by 65c ; Offers Guidance
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Reports Q2 Loss of $0.82, Beats on Revenue
-
-
-
-
-
-
-
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
-
-
-
-
-
-
-
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lu
-
-
-
-
-
-
-
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) and Novocure (NVCR) Report Phase 2 Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

